News

Check full video on YouTube: https://www.youtube.com/watch?v=csci5pl_8gY

We thank our customers and supporters by showcasing some highlights as well…

Valneva and and Instituto Butantan, producer of immunobiologic products, today announced the signing of definitive agreements for the development,…

21 Jan'21

mRNA expression of Fgf5 (red) and Otx2 (yellow) in mouse EpiLCs. (c) Christa Buecker, Max Perutz Labs

How multiple enhancer elements cooperate to drive expression of their target gene is poorly understood. New research from the lab of Christa Bücker…

18 Jan'21

380 million years ago, fish started to crawl out of the water to colonise land. The Australian lungfish – an endangered, air-breathing fish – is one…

15 Jan'21

The schematic cartoon shows rDNA genes, containing single nucleotide variations within the coding (yellow dot) and non-coding regions (orange dot), being transcribed by Pol I and processed to form functional ribosomes. (c) Jason Sims

Despite modern sequencing methods, determining the precise sequence of the genetic code for ribosomal RNA (rRNA) has been technically challenging due…

12 Jan'21

Valneva announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine,…

11 Jan'21

Changes in daylength are a well-established annual timing cue for animal behavior and physiology. An international collaboration of scientists led by…

11 Jan'21

Valneva announced it has appointed Perry Celentano as Chief Operating Officer (COO) on an interim basis to support the expansion of the manufacturing…

07 Jan'21

New toxin-antidote pairs discovered in nematode species – researchers from the Burga lab at IMBA – Institute of Molecular Biotechnology of the…

07 Jan'21

Valneva reported preliminary and unaudited cash and cash equivalents of €204.4 million at the end of December 2020, exceeding its guidance of between…

22 Dec'20

The Austrian Science Fund (FWF) has granted a second four-year funding period for the Doctoral Program “Signaling Mechanisms in Cellular Homeostasis”…

16 Dec'20

Valneva announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.

Biolution proudly presents its new demo reel

Valneva and Instituto Butantan Sign Final Agreement on Single-Shot Chikungunya Vaccine for Low and Middle Income Countries

Strength in numbers: how weak enhancers can be powerful gene regulators

Record-breaking lungfish genome reveals how vertebrates conquered land

Revealing the genetic code of ribosomal RNAs

Valneva in Advanced Discussions with European Commission to Supply up to 60 Million Doses of Inactivated, Adjuvanted COVID-19 Vaccine Candidate

More than just a sun tan: ultraviolet light helps marine animals to tell the time of year

Valneva Strengthens Management Team; Appoints Perry Celentano as Interim COO and David Lawrence as Acting CFO

Selfish elements turn embryos into a battlefield

Valneva Reports FY 2020 Cash of Over €200 Million

SMICH Doctoral Program receives funding by FWF

Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate